The effect of a new anti-inflammatory agent, the ethoxy methyl ester of N-(2,6-dichloro-m-tolyl)-anthranilic acid (A3), on platelet behaviour "in vivo" and "in vitro".
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents; D001157:Arterial Occlusive Diseases / Q000517:prevention & control; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005019:Ethyl Ethers / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D066298:In Vitro Techniques; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010653:Phenylbutazone / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D011517:Prothrombin Time; D011817:Rabbits; D051381:Rats; D013917:Thrombin / Q000494:pharmacology; D013927:Thrombosis / Q000517:prevention & control; D014050:Toluene / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D062367:ortho-Aminobenzoates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D005019:Ethyl Ethers; D062367:ortho-Aminobenzoates; D014050:Toluene; D013917:Thrombin; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin